Prediction of Postoperative Complications and Survival in Gastric Cancer Using Preoperative Blood Markers

February 27, 2026 updated by: Dong Peng, First Affiliated Hospital of Chongqing Medical University

Clinical Study on the Effect of Preoperative Serum Biomarkers on the Prognosis of Gastric Cancer

Gastric cancer is one of the most common cancers worldwide, especially in East Asia. Although surgery remains the main treatment, patients may experience postoperative complications and have varying long-term survival outcomes. Early identification of high-risk patients before surgery is important for improving treatment decisions and patient management.

This study aims to develop a prediction model based on routinely available preoperative blood test results and clinical characteristics to estimate the risk of postoperative complications and long-term survival in patients with gastric cancer. The model will be developed and validated using data from multiple medical centers.

By using easily accessible clinical information, this study seeks to provide a practical tool to help clinicians better assess patient risk before surgery, support personalized treatment planning, and improve overall patient outcomes.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Actual)

3400

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Patients diagnosed with gastric cancer and undergoing radical gastric cancer surgery at the First Hospital of Chongqing Medical University, the Second Hospital of Chongqing Medical University, and the Yongchuan Hospital of Chongqing Medical University.

Description

Inclusion Criteria:

  • patients aged ≥18 years;
  • patients diagnosed with gastric cancer by pathological biopsy before surgery;
  • patients without chemotherapy, radiotherapy, targeted and immunotherapy before enrolment;
  • willing to participate in this study and sign the informed consent;
  • complete clinical data.

Exclusion Criteria:

  • patients with other primary malignant tumours other than gastric cancer;
  • patients with systemic diseases such as severe cardiopulmonary insufficiency that affect the choice of treatment plan;
  • patients who are not suitable for enrolment as assessed by the investigator;
  • incomplete clinical data.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
the incidence of gastric cancer
Time Frame: From 18 years old until the developing gastric cancer, through study completion, an average of 5 year.
the diagnosis time of gastric cancer
From 18 years old until the developing gastric cancer, through study completion, an average of 5 year.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

First Affiliated Hospital of Chongqing Medical University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 1, 2010

Primary Completion (Actual)

November 1, 2024

Study Completion (Actual)

November 1, 2024

Study Registration Dates

First Submitted

November 12, 2024

First Submitted That Met QC Criteria

November 12, 2024

First Posted (Actual)

November 13, 2024

Study Record Updates

Last Update Posted (Actual)

March 3, 2026

Last Update Submitted That Met QC Criteria

February 27, 2026

Last Verified

February 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • ZZ2024-292-01

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

None of the three clinical centres conducting the study allowed the disclosure of patient information and data sharing.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Gastric Cancers

Clinical Trials on gastric cancer

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Malta

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe